Merck's Keytruda Resilience and Diverse Growth Drivers Underpin Bullish Outlook

Merck's flagship cancer drug, Keytruda, is poised to maintain robust revenue despite impending patent expiry risks, bolstered by new indications and the anticipated 20-year monopoly of KEYTRUDA QLEX. The pharmaceutical giant also benefits from significant growth in its Animal Health/Livestock segment, recording high single-digit increases. Furthermore, the company's new drug Winrevair is experiencing triple-digit growth, diversifying revenue streams. Analysts highlight Merck's healthy balance sheet, secure dividend payments, and reasonable valuation. This strong financial standing, coupled with resilient product performance, underpins a positive investment thesis. A pullback to the $100-$110 range or 50-day moving average levels is suggested as an opportune buying point for the stock.